A method of binding the endogenous and exogenous antigenic peptides to HLA-E, -F, -G as universal vaccines, wherein the antigenic peptides processed and presented by antigen-presenting cells are derived from auto-antigens, inflammatory molecules, cancer antigens, allergens, bacterial, fungal and viral antigens, and wherein antigen presenting cells are phenotypically or genetically modified for preferential loading antigenic peptides onto HLA-E, -F, -G, whereby vaccine-activated immune cells provide immune defense or orchestrate immune homeostasis to the vaccinated hosts.